PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENES

The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers. La présente invention co...

Full description

Saved in:
Bibliographic Details
Main Authors MU, Xinmeng, DI PIETRO, Alessandra, ALIMZHANOV, Marat, CHING, Keith Anthony, ROBBINS, Paul Brian
Format Patent
LanguageEnglish
French
Published 10.12.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers. La présente invention concerne des polythérapies comprenant un antagoniste de liaison à l'axe PD-1, le cancer ayant été prédéterminé comme ayant une ou plusieurs mutations génétiques dans un ou plusieurs gènes, comme ayant certains profils d'expression génique et/ou comme ayant d'autres biomarqueurs.
Bibliography:Application Number: WO2020EP65038